$1.36
-0.03 (-2.16%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where STXS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 2 observational · 2 with posted results
Held by 5 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Verition Fund Management LLC, RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 2.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| The MAGiC™ Cardiac Ablation European StudyNCT06019845Acute PerformanceOpen-label · Treatment | Not applicable | Recruiting | Device: MAGiC™ | Arrhythmias, Cardiac | 150 | 2027-12-31 | in 499 d | 2026-05-04 |
| RMN Versus Manual Epicardial Retrospective PMCFNCT04171479observationalAcute Success | — | Completed | Device: Epicardial mapping and/or ablation | Ventricular Tachycardia, Premature Ventricular Contraction | 40 | 2023-03-30actual | — | 2023-08-03 |
| Comparison of VT Ablation Outcomes Using Remote MAGNETIC Navigation Versus Manual Approach in a Low LVEF PopulationNCT02637947freedom from any VT in the overall cohortRandomized · Single-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: In the post-market environment, the RCT design did not allow achievement of enrollment goals | Device: catheter ablation using magnetic navigation, catheter ablation using manual navigation | Tachycardia, Ventricular | 182 | 2022-02-15actual | — | 2022-09-27 |
| Stereotaxis Idiopathic Ventricular Tachycardia (VT) StudyNCT01401608observationalChange in 24-hour Holter Monitor (number of extra ventricular beats) | — | Terminatedsponsor's stated reason: Difficult to recruit eligible subjects | Device: RF Ablation | Ventricular Tachycardia | 6 | Dec 2013actual | — | 2015-05-20 |
| Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures StudyNCT01656772results2015-06-04The Primary Effectiveness Endpoint is the Successful Navigation and EGM Recording of Each Pre-specified Pulmonary Vein Per Procedure Between Both the Control and the Investigational Device Groups.Randomized · Open-label · Treatment | Phase 3 | Completed | Device: Vdrive Lasso navigation · Procedure: Manual Lasso navigation | Atrial Fibrillation | 120 | Dec 2013actual | — | 2015-07-01 |
| Stereotaxis Study To Obliterate Persistent Ventricular TachycardiaNCT00851279results2015-08-24Percentage of Participants Free From VT at 1 Year Post-TreatmentOpen-label · Treatment | Phase 4 | Completed | Device: Magnetic irrigated ablation catheter | Ventricular Tachycardia | 53 | Oct 2012actual | — | 2015-08-24 |
| Stereotaxis Computed Tomography (CT) Co-Registration StudyNCT00994331The primary endpoint is to compare and evaluate the total contrast use between Groups A, B and C .Randomized · Open-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Study terminated due to lack of enrollment. | Procedure: Percutaneous coronary intervention | Coronary Artery Disease | 4 | Mar 2011actual | — | 2011-03-10 |
| PowerAssert Radio-Frequency (RF) Guidewire Coronary In-Stent Chronic Total Occlusion (CTO)NCT01131793Primary RF wire successOpen-label · Treatment | Phase 2 | Completed | Device: PowerAssert RF wire in crossing coronary in-stent chronic total occlusions | Coronary Artery Disease | 5 | Mar 2011actual | — | 2011-07-20 |
| HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes StudyNCT00370526Reduction in end systolic volume (ESV)Randomized · Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Insufficient enrollment | Procedure: Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement | Heart Failure, Congestive | 100 | Apr 2007actual | — | 2008-01-11 |
| MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic GuidanceNCT00370474The first primary endpoint for this trial is LV lead placement time defined as time from entry of the guidewire into the coronary sinus os to confirmed positioning of the lead tip at the target siteRandomized · Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Procedure protocol improved - study protocol became obsolete | Device: Bi-ventricular lead placement | Cardiac Resynchronization Therapy | 27 | — | — | 2007-06-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19